A lab-made peptide that prompts a clean pulse of the body's own growth hormone — the one effect reliably shown in people. Better body composition, bones, sleep, recovery, and slowed aging rest on growth hormone biology, not direct studies. Long-term safety, real-world benefit, and product quality remain genuinely unknown. (Full Review)

Protocol

Dose

~200 mcg

Typically 100–300 mcg per dose; conservative low start

Route & Frequency

Daily subcutaneous injection

Often combined with a GHRH analog; once to three times daily

Timing

Bedtime, empty stomach

Separated from food by ~2 hours to align with nocturnal GH surge

Time to effect

Growth hormone release

Immediate

Acute pulse within an hour of a dose

Sleep & recovery

Weeks

Perceptible effects typically reported over weeks

Body composition

2–3 months

Changes, if they occur, unfold with consistent use

Benefits

High: Acute growth hormone release

Medium: Favorable selectivity versus other growth hormone peptides

Low: Improved body composition; bone density support; better sleep quality and recovery

Speculative: Enhanced tissue repair and injury recovery; skin quality and cosmetic effects; general longevity and healthspan extension

Contraindications

Active or recent cancer

Pregnancy or breastfeeding

Children or adolescents with open growth plates

Key Interactions

Growth hormone and GHRH analogs (sermorelin, tesamorelin, CJC-1295)

Insulin and glucose-lowering drugs (metformin, sulfonylureas, insulin, SGLT2 inhibitors, GLP-1 agonists)

Corticosteroids (prednisone, dexamethasone)

Thyroid hormone (levothyroxine)

Additive GH/IGF-1 supplements (MK-677/ibutamoren, arginine)

Uncontrolled diabetes (HbA1c above ~8%), proliferative retinopathy

Risk & Side Effects

High: Unknown long-term safety

Medium: Impaired glucose tolerance and insulin resistance; fluid retention, joint pain, and carpal tunnel symptoms

Low: Injection-site and short-term tolerability reactions; product quality, contamination, and counterfeiting

Speculative: Theoretical cancer-promotion risk from elevated IGF-1; pituitary desensitization or altered endogenous regulation

Monitoring

Marker	Target	Why
IGF-1	Mid-to-upper age-adjusted range; avoid exceeding the top	Primary marker of downstream effect and key safety guardrail
Fasting glucose	70–85 mg/dL	Detects GH-driven rises in blood sugar early
HbA1c	<5.4%	Captures sustained glucose impact of GH elevation
Fasting insulin	2–5 µIU/mL	Detects early insulin resistance before glucose rises
IGFBP-3	Within age-adjusted reference range	Provides context for IGF-1 by reflecting GH axis activity
Thyroid panel (TSH, free T4, free T3)	TSH ~0.5–2.0 mIU/L; free T3/T4 mid-range	GH can shift T4-to-T3 conversion and unmask low thyroid
Complete blood count and comprehensive metabolic panel	Within conventional reference ranges	General safety screen for kidney, liver, and blood parameters

Cadence: Baseline before first dose, again at ~4–6 weeks, then every 3 months during use (IGF-1 and fasting glucose as priority repeat markers)

Qualitative Assessment

Sleep quality and depth
Energy levels and daytime alertness
Exercise recovery and reduction in post-training soreness
Body composition changes
Skin, hair, and nail quality
Onset of any warning symptoms (hand numbness/tingling, joint swelling, persistent water retention)

Ipamorelin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment